Steven David
@drspdavid
Radiation Oncologist at the Peter MacCallum Cancer Centre. Views are my own, healthy skeptic. #radonc
You might like
🔬 AVATAR trial published(ER+/HER2– MBC on AI + CDK4/6i): In OPD, SABR delayed therapy change (mPFS 9.9 mo) 🔷 44% on same Rx at 12 mo 🔷 36% at 24 mo Some received SABR 2–3× for new oligoprogressions—modified endpoints may better reflect its value. ascopubs.org/doi/10.1200/OA…
Extraordinary case at #SABR2025 by @drspdavid and De Mark Shaw @PeterMacRadOnc oligoprogressive #breastcancer without switching drug therapy. 8 years of SABR with #radonc, with preserved quality of life from the patient’s perspective!!! #bcsm
Register now for the next FREE #RSSwebinar on "The Role of Metastasis-Directed Therapy for Oligometastases and Oligoprogression in Breast Cancer" on 10/9 at noon ET featuring @drspdavid, @r_glicksman and @WinstonVuong; moderated by @radicalonc. therss.org/education/webi…
Congrats to Dr. Belle Sasse on this impactful study! 🎉 Collaboration between @MonashHealth & @PeterMacRadOnc shows metastatic breast MDMs changed treatment plans in 28.1% of patients, highlighting their invaluable role in care. 👉 Read: thebreastonline.com/article/S0960-…
🚩 Sharing our latest article: Here we show that dose dense AC-T, radiotherapy & age affects long-term lymphocyte counts post adjuvant #breastcancer treatment ?implications for IO therapy nature.com/articles/s4152… 👏 @J_DixonDouglas @GustaveRoussy @PeterMacRes @BCRFcure
Wonderful summary on #oligometastatic disease and #oligoprogression in #breastcancer by excellent speakers Prue Francis and @drspdavid @BCTrialsANZ #bct2024 Looking forward to AVATAR-2 ⚡️⚡️ @PeterMacRadOnc
Our phenomenal #radonc team!! A superbly productive and energising day of aspirations and strategic planning @PeterMacRadOnc #thefutureisbright 😎 @PeterMacCC @svporceddu
Big thank you to @TROGfightcancer and my supportive supervisor @drspdavid @PeterMacRadOnc for a fantastic opportunity to speak at this year’s ASM #TROG2024 #TROGASM24
The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!
The breast plenary session at #TROGASM24 continues as Emma Connolly took the stage with the latest update on the groundbreaking Stereotactic Radiotherapy for Oligoprogressive ER-positive Breast Cancer (AVATAR): A Phase II Prospective Multicentre Trial!
@piet_ost argues the case for SABR in oligometastatic #prostatecancer - a low toxicity intervention. To better select for patients who benefit most, think biomarkers of the future (genomics), and a role for SABR in mCRPC from ARTO trial #pcsm #radonc #SABR2023
Off and running at this year’s #SABR2023 @PeterMacCC @PeterMacRadOnc. Sold out symposium.
Metastatic #breastcancer at #COSA23 . A/Prof Steven David takes the stage to discuss future directions in #oligometastatic breast cancer care. Alongside A/Prof Shom Goel & Dr Stephen Luen (also from @PeterMacCC) & Kerry Patford, breast care nurse. 👏 @drspdavid @COSAoncology
A/Prof Steven David sharing a phase 2 trial of stereotactic #radiotherapy for oligoprogressive ER positive breast #cancer #RANZCR2023
#AVATAR was a standout at ASTRO this year. Kudos for the remarkable effort!
The COSA AM is in Melbourne this November. It's a highlight of the Australian oncology calendar, and I'm looking forward to presenting on oligometastatic breast cancer. Registrations are at bit.ly/3Mwpunk Hoping to see you there! #COSA23
Thanks to the patients and the trial team. AVATAR presented at #ASTRO2023 #radonc @PeterMacRadOnc
Congratulations @drspdavid 👏👏😊 huge amount of work, presented so clearly and with beautiful slides ☺️ @PeterMacRadOnc @PeterMacRes @TROGfightcancer #breastcancer team #ASTRO2023
@drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!
@drspdavid -late breaking abstract #ASTRO23 - investigating SANR for patients with oligoprogression in ER+ve Her2 -ve #breastcancer. Primary EFS endpoint met, and 1 in 3 patients amenable to repeat SABR, resulting in ‘real world’ mPFS of 10.1mo. 👏🏽👏🏽👏🏽🍾 congrats!!!
United States Trends
- 1. Falcons 30.2K posts
- 2. Bears 59.1K posts
- 3. Myles Garrett 2,679 posts
- 4. Ravens 18.5K posts
- 5. Bryce Young 16.4K posts
- 6. Chiefs 31.1K posts
- 7. Rams 14.8K posts
- 8. Josh Allen 22.7K posts
- 9. Vikings 29.7K posts
- 10. #KeepPounding 5,787 posts
- 11. Chargers 21K posts
- 12. JJ McCarthy 11.8K posts
- 13. Panthers 27.2K posts
- 14. Mahomes 6,891 posts
- 15. Bengals 24.8K posts
- 16. Packers 40.9K posts
- 17. Hyatt 4,765 posts
- 18. Troy Franklin 1,264 posts
- 19. Sam Darnold 2,287 posts
- 20. Chase 101K posts
You might like
-
Belinda Campbell
@belinda_campbe -
RadOncResearch
@HegiFiona -
Peter Mac Radiation Oncology
@PeterMacRadOnc -
Farshad Foroudi
@FarshadForoudi -
Michael MacManus
@MP_MacManus -
Wee Loon Ong
@weeloonong -
Sweet Ping Ng
@SweetPingNg -
Cristian Udovicich
@cristian_udo -
Peppe Sasso
@radiopeppe -
Michelle Li
@DrMichelleLi -
Sarat Chander
@saratchanderRO -
Stephen Chin
@schin_au -
Prostate_doc
@SukiGill01
Something went wrong.
Something went wrong.